Compare PINE & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PINE | BDSX |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.1M | 276.2M |
| IPO Year | 2019 | 2020 |
| Metric | PINE | BDSX |
|---|---|---|
| Price | $16.64 | $8.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $19.90 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 184.4K | 69.7K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | $60,532,000.00 | ★ $88,499,000.00 |
| Revenue This Year | $31.91 | $26.35 |
| Revenue Next Year | $10.40 | $20.40 |
| P/E Ratio | $40.21 | ★ N/A |
| Revenue Growth | 15.90 | ★ 24.08 |
| 52 Week Low | $15.29 | $5.26 |
| 52 Week High | $21.99 | $31.97 |
| Indicator | PINE | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 18.42 |
| Support Level | $16.62 | N/A |
| Resistance Level | $19.93 | $11.57 |
| Average True Range (ATR) | 0.63 | 2.10 |
| MACD | 0.03 | -0.93 |
| Stochastic Oscillator | 37.48 | 6.32 |
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.